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Abstract The World Health Organization has included three bunyaviruses posing an increasing
threat to human health on the Blueprint list of viruses likely to cause major epidemics and for which
no, or insufficient countermeasures exist. Here, we describe a broadly applicable strategy, based
on llama-derived single-domain antibodies (VHHs), for the development of bunyavirus
biotherapeutics. The method was validated using the zoonotic Rift Valley fever virus (RVFV) and
Schmallenberg virus (SBV), an emerging pathogen of ruminants, as model pathogens. VHH building
blocks were assembled into highly potent neutralizing complexes using bacterial superglue
technology. The multimeric complexes were shown to reduce and prevent virus-induced morbidity
and mortality in mice upon prophylactic administration. Bispecific molecules engineered to present
two different VHHs fused to an Fc domain were further shown to be effective upon therapeutic
administration. The presented VHH-based technology holds great promise for the development of
bunyavirus antiviral therapies.
Introduction
Facilitated by globalization and climate change, arthropod-borne viruses (arboviruses) increasingly
pose a threat to human and animal health (Gould et al., 2017). Although for some arboviruses vac-
cines are available that can be used to prevent or control outbreaks, for the vast majority of emerg-
ing arboviruses no countermeasures are available. Rift Valley fever virus (RVFV), a phlebovirus within
the order Bunyavirales, is prioritized by the World Health Organization (WHO) as being likely to
cause major epidemics for which no, or insufficient countermeasures exist. RVFV is currently confined
to the African continent, the Arabian Peninsula and several islands off the coast of Southern Africa,
where it causes recurrent outbreaks (Clark et al., 2018). The world-wide distribution of competent
mosquito vectors and susceptible animals underscores the risk for emergence in currently unaffected
areas. In endemic areas, RVFV causes major epizootics among livestock, characterized by abortion
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storms and large-scale mortality among newborn ruminants. Importantly, the virus also infects
humans, either through direct contact with infected animal tissues or via the bites of infected mos-
quitoes (Hartman, 2017). Infected individuals generally present with mild to severe flu-like symp-
toms, however a minority of patients may develop encephalitis or hemorrhagic fever.
In addition to members of the family Phenuiviridae, like RVFV, members of the family Peribunya-
viridae, genus Orthobunyavirus, may also cause severe disease in humans and animals. In 2011, the
incursion of Schmallenberg virus (SBV) in Europe demonstrated that orthobunyaviruses are capable
of spreading very efficiently across new territories. SBV infections are associated with fever and
reduced milk production in cows and severe malformations in offspring of both large and small rumi-
nants (Hoffmann et al., 2012; van den Brom et al., 2012). SBV is categorized as a biosafety level-2
pathogen and is not pathogenic to humans, facilitating its use as a model of zoonotic orthobunyavi-
ruses that require a higher level of containment (Golender et al., 2015; van Eeden et al., 2014;
van Eeden et al., 2012).
At the moment, no effective antiviral therapy is available to treat bunyavirus infections in humans.
Patients essentially rely on supportive care. Some promising pre-clinical and clinical data have been
obtained with small molecules, mainly nucleoside analogues, that interfere with viral replication
(Gowen and Hickerson, 2017). Recent X-ray crystallography and cryo-electron microscopy/tomog-
raphy data have provided novel insights into the bunyavirus glycoprotein architecture that may facili-
tate the development of bunyavirus antibody therapies in the future (Wu et al., 2017b;
Hellert et al., 2019; Halldorsson et al., 2018). After vaccines, antibody therapies are considered
the most effective tools to fight (re)emerging life-threatening viral infections (Jin et al., 2017).
A very wide range of approaches are currently used to isolate natural antibodies and to design
synthetic constructs. Most of these efforts are based on neutralizing antibodies or antibody frag-
ments of murine or human origin. In general, these molecules consist of heavy and light polypeptide
chains linked by disulphide bonds. Interestingly, in only a few species such as camelids and nurse
sharks, heavy chain-only antibodies (HCAbs) are found, of which the antigen binding domain can be
expressed as a single-domain antibody (sdAb) (Arbabi-Ghahroudi, 2017). Camelid derived sdAbs,
known as VHHs, are increasingly used as tools in medicine, including virus neutralization (Wu et al.,
2017a; De Vlieger et al., 2018). VHHs are intrinsically highly soluble molecules and due to their dis-
tinctive structure with extended antigen-binding CDR3 region and overall small size, some are able
to target unique (cryptic) antigenic sites not accessible to conventional antibodies (Muylder-
mans, 2013). VHHs with nanomolar or even picomolar affinity targeting a broad spectrum of anti-
gens have been described (Jin et al., 2017; Arbabi-Ghahroudi, 2017). The single-domain nature
additionally allows easy genetic manipulation and favors efficient expression in various heterologous
systems including microorganisms (Harmsen and De Haard, 2007a; Liu and Huang, 2018).
So far, VHHs have been explored as tools for a wide range of applications including their use as
therapeutic agents (Wu et al., 2017a; Harmsen and De Haard, 2007a; Bannas et al., 2017;
Traenkle and Rothbauer, 2017; Gonzalez-Sapienza et al., 2017). With respect to virus neutraliza-
tion, a multimeric VHH has shown great promise in counteracting severe pulmonary disease in
infants caused by respiratory syncytial virus (RSV) (Detalle et al., 2016). The therapeutic potency of
complexes consisting of multimers of the same VHH (multivalent) or combinations of VHHs targeting
different antigenic sites (multispecific) is explained by their improved avidity, selectivity and kinetics
compared to individual VHHs (Hultberg et al., 2011). Although techniques to use VHHs as building
blocks to generate multifunctional molecules are well established, selection of the optimal VHH com-
bination and optimal VHH formats is still challenging (Iezzi et al., 2018).
Recently, the discovery of ’bacterial superglues’ has enabled the creation of unique protein archi-
tectures. The superglues are comprised of a bacterially-derived peptide and a small protein able to
form unbreakable isopeptide bonds (Veggiani et al., 2014). The first bacterial superglue was devel-
oped by splitting the immunoglobulin-like collagen adhesion domain (CnaB2) of the fibronectin
binding protein (FbaB) of Streptococcus pyogenes (Zakeri et al., 2012) into a peptide and a protein
fragment referred to as SpyTag and SpyCatcher. When the two peptides meet, an amide bond is
formed which is highly specific and irreversible. Covalent bond formation occurs within minutes
upon mixing and is highly robust under various conditions (Zakeri et al., 2012). The potency of Spy-
Tag:SpyCatcher has already found applications in various disciplines and triggered the search for
various additional protein and peptide partners (Veggiani et al., 2016; Tan et al., 2016).
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Here, we selected and characterized RVFV and SBV-specific VHHs targeting receptor binding gly-
coprotein domains, and used bacterial superglues to create virus neutralizing VHH complexes that
reduced and prevented morbidity and mortality in mouse models. Selected RVFV VHHs were subse-
quently reformatted into human Fc-based bispecific chimeric HCAbs that showed protection in pre-
and post-exposure treatments.
Results
Selection of RVFV and SBV-specific VHHs
To obtain a source of RVFV and SBV-specific VHHs with potential neutralizing activity for the respec-
tive viruses, llamas were inoculated with the live-attenuated RVFV vaccine strain Clone 13, RVFV
virus-like particles (VLPs) or SBV NL-F6 (Figure 1A). All inoculated animals responded well with virus-
specific neutralizing antibodies in serum above a 50% neutralizing titer of 500 (Figure 1B;
Wichgers Schreur et al., 2017; Loeffen et al., 2012). The B-cell-derived VHH phagemid libraries
contained >107 unique clones per animal.
RVFV and SBV-specific VHHs were isolated from VHH phage display libraries by pannings with
the RVFV Gn ectodomain (RVFV-Gnecto) (de Boer et al., 2010) or the SBV Gc head domain (SBV-
Gchead) (Figure 1C; Hellert et al., 2019), previously described as the Gc N-terminal subdomain of
234 amino acids (Gc Amino) (Wernike et al., 2017). Both RVFV-Gnecto and SBV-Gchead are consid-
ered to be the main targets of neutralizing antibodies against the respective viruses (Hellert et al.,
2019; Wernike et al., 2017; Roman-Sosa et al., 2017; Kortekaas et al., 2010; Kortekaas et al.,
2012). Supernatants of induced clones were screened for RVFV-Gnecto and SBV-Gchead specificity by
indirect ELISA and immunoperoxidase monolayer assay (IPMA). In total 62 unique RVFV-Gnecto-spe-
cific clones that grouped into 16 CDR groups (15 CDR3 groups) and 15 unique SBV-Gchead-specific
clones that grouped into 6 CDR3 groups were identified (Figure 1D; Figure 1—figure supplement
1). One representative VHH per CDR group was subsequently produced in yeast (Figure 1E). All
yeast expressed VHHs were confirmed to recognize soluble RVFV-Gnecto, or SBV-Gchead by ELISA
(Figure 1F,G) and/or were found to bind to fixed viral antigen in infected cells (Figure 1—figure
supplement 2).
RVFV and SBV VHHs recognize distinct antigenic sites
To determine the number of antigenic sites targeted by the different VHHs, RVFV-Gnecto and SBV-
Gchead-specific competition ELISAs were performed. The RVFV VHH panel (N = 16) was shown to
target three independent antigenic sites within RVFV-Gnecto, referred to as the red, blue and yellow
antigenic sites (Figure 2A). When compared to the VHHs of the blue and the yellow antigenic sites,
all of the VHHs of the red antigenic site did not show typical sigmoidal curves, suggesting markedly
reduced avidity for monomeric Gnecto (Figure 1F). The SBV-specific VHHs showed a more complex
pattern of competition (Figure 2B). SB10 (beige) clearly targets an antigenic site that does not over-
lap with the sites targeted by the other five VHHs. SB12 and SB13 (orange) recognize the same anti-
genic site that does not overlap with the site targeted by SB11 (green). However, SB9 and SB14
(violet) show reciprocal competition with each other and SB9 competes (reciprocally) with SB11.
SB14 shows non-reciprocal competition with SB12 and SB13, which strongly suggests that the epito-
pes of SB9, SB11, SB12, SB13 and SB14 are all in very close proximity (Figure 2B).
Mapping of the RVFV VHHs to the RVFV-Gn head domain
The N-terminal 154–469 amino acids of RVFV-Gnecto, now known as the RVFV-Gn head domain, was
recently crystallized and shown to comprise three subdomains; subdomain A (or I), b ribbon domain
(II) and domain B (III) (Wu et al., 2017b; Halldorsson et al., 2018). To assess whether the VHHs tar-
get a specific subdomain, the head domain as well as the individual subdomains were expressed
using the baculovirus expression system. The subdomains were expressed successfully (Figure 2C)
and binding to the RVFV VHHs was assessed by indirect ELISA (Figure 2D). The results show that
the yellow antigenic site, which is targeted by RV104, RV136 and RV148, is located on subdomain B
and that the blue antigenic site, recognized by RV107 and RV115, is primarily located on the b-rib-
bon domain. The red antigenic site could not be mapped to a specific subdomain, suggesting that
this site is present at a subdomain interface. Gn, as part of the Gn/Gc heterodimer, is organized
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Figure 1. Selection and expression of RVFV and SBV-specific VHHs. (A) Illustration of the llama immunization strategy to obtain a source for RVFV and
SBV-specific VHHs. (B) RVFV and SBV-specific virus neutralizing responses in llama sera determined by virus neutralization test (VNT) before (pre) and
post immunization. Neutralizing antibody titers were measured by endpoint titration and calculated as 50% neutralization. (C) Schematic presentation of
the VHH library construction and phage display selections. Blood lymphocyte RNA was used as a template for VHH-specific PCRs and purified
Figure 1 continued on next page
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similarly in both hexamers and pentamers on the RVFV particle, of which Gn is most exposed to the
immune system. We mapped the antigenic sites to the previously proposed Gn structure within the
pentameric capsomer density (Figure 2F).
Mapping of the SBV VHHs on the SBV-Gc head domain
The SBV-Gc head domain is the most exposed feature on the virus envelope, and based on homol-
ogy with other orthobunyaviruses, it is believed to reversibly form homotrimers among neighboring
Gc molecules (Hellert et al., 2019). Crystal structures of the head domain in complex with two neu-
tralizing murine mAbs, referred to as 1C11 and 4B6, have recently shown that 1C11 binds to the api-
cal end of the head domain, near the N686 glycosylation site, and that 4B6 binds to the opposite,
basal end of the head domain, near its connection to the stalk (Hellert et al., 2019). Binding of
either antibody is sterically incompatible with head domain trimerization, suggesting that neutraliza-
tion may at least be partially mediated by destabilization of the spike’s quaternary structure
(Hellert et al., 2019). Competition ELISAs with 1C11 and 4B6 and our SBV VHH panel suggests that
SB11 and SB14 target the same antigenic site as 1C11 at the apical end of the domain, whereas no
competition was observed with 4B6 (Figure 2B). For SB10, of which the antigenic site is independent
from the others, we generated an escape mutant carrying the single point mutation Y541C located
directly at the head domain’s contact area with the stalk (Figure 2E,G). This site likely acts as a hinge
allowing the head domain to adopt different orientations relative to the virion surface (Hellert et al.,
2019), and antibody binding is thus expected to restrain the local mobility of the spike.
Multimeric VHH complexes show superior neutralization activity
The virus neutralizing activity of selected VHHs, representative for each antigenic site, was evaluated
with RVFV and SBV-specific virus neutralization tests (VNTs). At nM range concentrations, no neutral-
ization was observed for any of the monovalent VHHs (Figure 3; left panel of the figure and diagonal
set of bars). Since synergistic effects have been reported for combinations of monoclonal antibodies
in bunyavirus neutralization (Besselaar and Blackburn, 1992), we subsequently tested mixtures of
VHHs. Combining two VHHs in the VNT assays resulted in moderate neutralization for some SBV
VHH combinations (ND50 around 200 nM) whereas still no neutralization was observed for RVFV
VHH mixtures (Figure 3; left part of the figure with double colored bars). We therefore assessed
whether multimerization supports efficient neutralization. In order to facilitate the screening of a
large set of bivalent and bispecific complexes including various linker lengths and without the need
to construct a lot of expression plasmids, we used the advantageous properties of bacterial super-
glue. VHHs were expressed with Spy- and SnoopTags and flexible scaffolds consisting of one, two or
three elastin-like protein (ELP) domains were expressed with Spy- and SnoopCatcher domains. By
simply mixing the tagged VHH versions with the Catcher containing ELP scaffolds, bivalent and bis-
pecific complexes were constructed (Figure 4). The VNT assays subsequently revealed that several
multimeric complexes very efficiently neutralized with ND50 <10 nM (Figure 3; middle and right pan-
els). For RVFV, targeting of two distinct antigenic sites seemed a prerequisite to enable efficient neu-
tralization (Figure 3A), whereas for SBV both bivalent and bispecific complexes were capable of
neutralization (Figure 3B). Interestingly, the length of the scaffolds did not have a major effect on
neutralization efficiency of the RVFV VHH complexes, whereas the length did influence efficacy of
the SBV complexes. Complexes based on the ELP3 scaffold (the longest tested) showed markedly
higher neutralization efficiencies.
Figure 1 continued
fragments were cloned into phagemids generating a phagemid library. Following phagemid transduction, the purified phage library was screened for
antigen-specific phages. (D) Summarizing table of the VHH clone selection showing the number (#) of unique clones identified and the number of CDR
groups per antigen. (E) SDS-PAGE of yeast-expressed RVFV and SBV-specific VHHs. SB10 was shown to be partly N-glycosylated as confirmed by
PNGase F based deglycosylation (lane SB10*). (F) RVFV-Gnecto and (G) SBV-Gchead-specific indirect ELISAs. The color coding of the individual VHHs is
based on the outcome of the competition ELISA result as presented in Figure 2A and B.
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. VHH amino acid sequence alignment.
Figure supplement 2. VHH specificity determined by immunoperoxidase monolayer assay (IPMA).
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Figure 2. Characterization of VHH binding sites. (A) RVFV and (B) SBV-specific VHHs and antibodies were tested in competition ELISA using RVFV-
Gnecto and SBV-Gchead as antigens. Competition is expressed as percentage of blocking. A percentage above 50% is considered efficient blocking and
strongly suggests that the test VHH binds at an overlapping site in the antigen as the blocking VHH. For SBV, competition was additionally assessed for
the 1C11 and 4B6 mouse mAbs (Hellert et al., 2019). The RVFV-specific VHHs clustered into three groups each targeting a different antigenic site in
RVFV-Gnecto and the SBV VHH panel was shown to target 4 different antigenic sites in SBV-Gchead (of which the green, violet and orange sites are
shown to be partly overlapping). Since SB11 and SB14 showed efficient competition (although non-reciprocal) with 1C11, the green, violet and orange
antigenic sites are expected to be located at the apical end of the SBV-Gchead domain. (C) SDS-PAGE of the baculovirus produced head, A, b-ribbon
and B subdomains of RVFV-Gnecto. The lowest band in the subdomain A lane is expected to be the result of proteolytic cleavage. (D) RVFV-Gnecto
subdomain-based VHH ELISAs. Wells were coated with the indicated subdomains and VHH binding was assessed with a HRP-conjugated goat anti-
llama IgG. (E) SB10 escape mutant selection. Briefly, wildtype SBV was sequentially passaged in the absence or presence of SB10. Following passage 6,
the Gchead coding region was sequenced and SB10 neutralization was quantitatively assessed. (F) Model of a pentameric RVFV spike. The RVFV Gn/Gc
heterodimer within a penton (PDB: 6F9F, Halldorsson et al., 2018) is color-coded by domains. The Gn head domain is outlined in black. Arrows
indicate approximate positions of the two mapped antigenic sites. (G) Model of a trimeric SBV spike based on the monomeric SBV crystal structure
(PDB: 6H3S, Hellert et al., 2019) and the trimeric BUNV cryo-ET map (EMDB: EMD-2352, Bowden et al., 2013). A protomer is color-coded by
Figure 2 continued on next page
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Figure 2 continued
domains and the Gc head domain is outlined in black. The two N-glycans are labelled with the positions of their respective asparagine residues and the
position of the SB10 escape mutation is indicated with a star. Arrows indicate approximate positions of the antigenic sites. Antigenic sites for which
evidence is inconclusive are indicated with question marks (green and beige sites).
Figure 3. RVFV and SBV-specific neutralization by monovalent VHHs and bacterial superglue-assembled VHH complexes. (A) RVFV- and (B) SBV-
specific monovalent VHHs, VHH combinations and bivalent and bispecific ELP-based VHH complexes were tested in a RVFV or SBV-specific VNT assay.
Complexes were formed by mixing the tagged versions of the VHHs with the indicated Catcher-containing ELP scaffolds of different lengths (Figure 4).
Mixtures were subsequently pre-incubated with virus before adding them to susceptible cells. The ND50 values refer to total VHH per reaction as
neutralization might be the result of cooperative action of VHH complexes and free VHHs. Averages of two biological replicate experiments are
presented. Individual VHHs are color-coded based on the antigenic site they recognize as determined by competition ELISA (Figure 2A and B).
Generally, most efficient neutralization was observed with multimerization of VHHs that each target a different antigenic site.
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Prophylactic administration of ELP-based VHH complexes reduces
morbidity and mortality in mice
Following the in vitro neutralization experiments, selected bivalent and bispecific complexes were
evaluated in mouse infection experiments. To extend the in vivo half-life, the complexes were
expressed with an albumin binding domain (ABD) (Figure 5A,B,C). Binding of a VHH complex to cir-
culating albumin is expected to extend the half-life not only due to an increased size of the complex,
but also as a result of recycling through the neonatal Fc receptor (FcRn) (Mehand et al., 2018;
Jacobs et al., 2015). Additionally, one trispecific RVFV VHH complex was constructed and evaluated
to take the bacterial superglue approach to the next level and to make a construct targeting the
red, blue and yellow antigenic sites within the RVFV-Gnhead domain simultaneously. To enable the
Figure 4. Bacterial superglue-based VHH formatting. (A) SDS-PAGE of ELP-based scaffolds with an N-terminal SnoopCatcher and a C-terminal
SpyCatcher domain. (B) SDS-PAGE of RVFV and (C) SBV-specific VHHs expressed with a C-terminal Snooptag or Spytag. The untagged variants were
expressed with the llama antibody long hinge region. (D) Illustration of the bacterial superglue-based site-directed formation of a bispecific or bivalent
VHH complex. (E) SDS-PAGE of the bacterial superglue-based formation of bivalent and bispecific VHH complexes using ELPs of various length. VHH
RV115 and VHH RV150 were used as an example for VHH-A and VHH-B, respectively.
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Figure 5. Efficacy of RVFV and SBV-specific ELP-based VHH complexes in mice. (A) Illustration of ELP-based VHH complexes comprising an albumin
binding domain (ABD). (B) SDS-PAGE of purified RVFV and SBV-specific ELP-VHH complexes. Uncoupled VHHs were removed by a Strep-tag based
purification following the coupling. The asterisks (*) indicate the glycosylated variants with higher molecular weights. (C) Species-specific albumin ELISA
of the ABD containing ELP scaffold. Human, mouse or bovine albumin was coated at a 10 mg/ml concentration and the trispecific ELP scaffold
containing an ABD domain (see A) was incubated in a dilution series. Binding was visualized with a Strep-Tactin-HRP conjugate. (D) Indirect RVFV-
Gnecto and (E) SBV-Gchead ELISA of purified RVFV and SBV-specific VHH complexes. (F) Neutralizing activity of the purified VHH complexes as
Figure 5 continued on next page
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construction of this trispecific complex we made use of a third bacterial superglue; SdyTag and Sdy-
Catcher (Veggiani et al., 2014). The specificity of all multimeric complexes to bind to RVFV-Gnecto
or SBV-Gchead was confirmed by indirect ELISA (Figure 5D,E) and efficient neutralization at nanomo-
lar scale was confirmed by VNT (Figure 5F).
Mice were inoculated once with the complexes, followed by a lethal challenge dose of either
RVFV or SBV. RVFV-specific complexes were evaluated in a BALB/c mouse model and SBV-specific
complexes in IFNAR-/- mice (Figure 5G,H; Wernike et al., 2012). The results of the RVFV mouse
experiment showed that in the absence of the ABD domain (RV104-ELP2-RV107) morbidity and mor-
tality could not be prevented or delayed, whereas treatment with both RV104-ELP2ABD-RV107 and
RV104-ELP2ABD-RV150 resulted in a marked delay in mortality, of which the delay was most pro-
nounced for RV104-ELP2ABD-RV107 (Figure 5I). Interestingly, the trispecific RV104-ELP-RV150-
ELPABD-RV107 complex protected the mice most efficiently, thereby suggesting that targeting of up
to three antigenic sites simultaneously is very effective.
For SBV, the SB10-ELP2ABD-SB10 complex prevented mortality in 5 out of 6 mice whereas the
SB9-ELP2ABD-SB10 complex protected all of the inoculated mice (Figure 5J). In both groups, none
of the surviving animals showed any clinical signs of disease or significant weight loss. In addition,
for all the antibody treated mice viral RNA loads in blood and tissue samples were markedly reduced
in comparison to the control animals (Figure 5—figure supplement 1).
Formation and in vivo potency of bispecific llama-human chimeric
antibodies
To improve the potency of the RVFV VHHs, we designed and constructed a llama-human chimeric
bispecific format that encompass effector functions similar as conventional immunoglobulins. More-
over, we aimed to generate HCAbs that are suitable for therapeutic application in humans and with
good manufacturability. We started with a human IgG1 CH2 and CH3 backbone, which enables bind-
ing to complement factor C1q and Fc receptors of immune cells triggering their activation. The
interface between the CH2–CH3 domains also contains the binding site for the FcRn, responsible for
the prolonged half-life of IgG, placental passage, and transport of IgG through mucosal surfaces
(Vidarsson et al., 2014). Several bivalent and/or bispecific hIgG1Fc-VHH fusions were constructed
(Figure 6A,B) and produced at small scale in HEK 293 T cells (Laventie et al., 2011). In line with the
ELP results, efficient neutralization at ND50 <1 nM was mainly observed with the bispecific constella-
tions (Figure 6C) despite binding avidities to Gnecto that were highly similar (Figure 6D). The two
most promising bispecific Fc fusions, 150-hIgG1Fc-104 and 107-hIgG1Fc-104 were subsequently pro-
duced at medium scale using a Chinese Hamster Ovary (CHO) cell-based transient expression plat-
form (20 L) in disposable rocking bioreactors (Daramola et al., 2014). The purified material was
subsequently tested in the RVFV BALB/c mouse model. In addition to prophylactic administration,
therapeutic efficacy was also evaluated (Figure 6E). The results show that 60-100% protection was
achieved with prophylactic administration and, remarkably, 60% protection was achieved after thera-
peutic administration (Figure 6F,G). Altogether, these results emphasize that VHH-based biothera-
peutics hold great promise for the treatment of bunyavirus infections either prophylactically or
therapeutically.
Discussion
Bunyaviruses pose a clear and present danger to both animal and human health. The WHO recog-
nized the threat for human health by including three bunyaviruses; RVFV, Crimean-Congo hemor-
rhagic fever virus (CCHFV) and severe fever with thrombocytopenia syndrome virus (SFTSV), on the
Figure 5 continued
determined by RVFV and SBV-specific VNTs. The ND50 values refer to the concentration of complexes. (G) Illustration of the RVFV and (H) SBV mouse
models. (I) Survival curve of RVFV infected mice pre-treated with 150 mg of the RVFV-specific VHH complexes. (J) Survival curve of SBV-infected mice
pre-treated with either 200 mg of SB10-ELP2ABD-SB10 or 100 mg SB10-ELP2ABD-SB9.
The online version of this article includes the following figure supplement(s) for figure 5:
Figure supplement 1. ELP-based SBV-specific VHH complexes reduce viremia.
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Blueprint list of viruses likely to cause future epidemics and for which no countermeasures are cur-
rently available (https://www.who.int/blueprint/priority-diseases/en/). Although for some bunyavi-
ruses veterinary vaccines are available or in development, for humans neither registered vaccines nor
effective therapies exist.
The lack of knowledge about bunyavirus glycoprotein structures and immunogenic domains
together with rudimentary knowledge on mechanisms of neutralization, have hampered the develop-
ment of antibody-based bunyavirus therapies. However, novel structural data on the glycoproteins,
obtained from combined X-ray and cryo-electron microscopy/tomography of whole virions for some
members of the Bunyavirales provide now exciting new opportunities (Wu et al., 2017b;
Figure 6. Llama-human chimeric antibodies protect mice from lethal RVFV infection. (A) Illustration of the VHH and hIgG1Fc-based llama-human
chimeric antibodies. (B) SDS-PAGE of the purified chimeric antibodies under non-reducing and reducing conditions. (C) Neutralizing activity of the
purified chimeric antibodies expressed as ND50. (D) Indirect RVFV-Gnecto-based ELISA of the chimeric antibodies. (E) Illustration of the mouse
experiment setup. (F) Survival curve of RVFV-infected mice treated with 200 mg 150-hIgG1Fc-104. (G) Survival curve of RVFV-infected mice treated with
200 mg 107-hIgG1Fc-104. * These chimeric antibodies were produced at medium scale in CHO cells.
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Hellert et al., 2019; Halldorsson et al., 2018; Allen et al., 2018). For RVFV and SBV, a limited num-
ber of conventional mouse and rabbit mAbs as well as human antibodies have been described with
neutralizing activity (Wu et al., 2017b; Hellert et al., 2019; Besselaar and Blackburn, 1992;
Allen et al., 2018; Wang et al., 2019; Wernike et al., 2015a). With this study, i) we provide a whole
panel of VHHs targeting RVFV or SBV, ii) show neutralizing activity of VHH-based complexes in vitro
and in vivo and, iii) provide a broadly applicable method for the development of VHH-based
biotherapeutics.
We specifically harnessed the advantageous characteristics of VHHs in combination with bacterial
superglues to develop highly potent virus neutralizing complexes. A major advantage of the pre-
sented approach over more conventional approaches is the modularity and subsequent flexibility
and directionality in complex construction, making selection of the most potent complexes a rela-
tively easy task. This modularity additionally ensures efficient production, while genetic fusion of
VHHs generally results in decreased production yields. Moreover, interference with CDRs is limited
due to the flexibility in positioning of the superglue tags in the VHHs, particularly when compared to
VHHs linked by genetic fusion, where N-terminal fusions can decrease affinity (Els Conrath et al.,
2001). Multimeric complexes have not only proven effective in neutralizing viruses, but the pre-
sented bacterial superglue and module-based assembly strategy may also facilitate the development
of biotherapeutics targeting cancer and toxins. Interestingly, a related approach primarily based on
SpyTag-SpyCatcher interactions has recently shown promise to functionally inactivate the human epi-
dermal growth factor receptor 3 (HER3) complex (Alam et al., 2018). A potential disadvantage of
using bacterial superglues in therapeutics is their intrinsic immunogenicity, leading to immune
responses that do not contribute to protection and may even reduce efficacy, particularly with suc-
cessive treatments. Nevertheless, the bacterial superglue strategy finds its added value, as we
showed, as a very efficient intermediate step for identification of potent VHH combinations. After
optimal combinations of VHHs are identified, these can be used to develop bispecific constructs
with human IgG1 Fc domains.
One of the most profound observations we made in our study was the very strong synergistic
effects in neutralization upon targeting of two or three different antigenic sites simultaneously. The
synergistic effect of mixtures of antibodies targeting two or more distinct antigenic sites on RVFV
virions was already reported more than 25 years ago by Besselaar and Blackburn (1992). They
showed that conventional non-neutralizing RVFV monoclonal antibodies efficiently neutralized when
they were used in combination (Besselaar and Blackburn, 1992). The requirement to target more
than one antigenic site for effective bunyavirus neutralization might be related to the broad range of
receptor and attachment molecules used for viral attachment and entry in both insect and mamma-
lian cells of which several are of non-proteinaceous nature (Albornoz et al., 2016). Remarkably, we
did not observe efficient neutralization by simply mixing VHHs targeting two distinct antigenic sites.
Efficient neutralization required conjugation of the VHHs to a larger scaffold. Only these larger com-
plexes were found to reduce or even prevent virus infection. Several mechanisms could explain the
higher efficacy of multimeric complexes, including more efficient interference with receptor binding
or interference with fusion through blocking viral glycoprotein conformational changes. Cross-linking
of the glycoproteins may also reduce their overall degrees of freedom thereby preventing the glyco-
protein shell to disassemble, which is a crucial step in the fusion process. Finally, binding of the com-
plexes to multiple sites at the virion surface may facilitate complement activation and/or
opsonization.
To gain insight into the mechanisms of RVFV neutralization, the VHHs were mapped on the Gn
glycoprotein. This showed that all selected RVFV VHHs bind to the head domain of the Gn glycopro-
tein. In the virion context, Gn forms heterodimers with Gc and assembles into capsomers that are
organized into an icosahedral lattice with a T = 12 quasisymmetry (Halldorsson et al., 2018;
Sherman et al., 2009; Huiskonen et al., 2009). Gn is involved in receptor binding and Gc, as a class
II fusion protein, is responsible for fusion of the viral membrane with the endosome (Guardado-
Calvo et al., 2017; Kielian, 2006). To prevent premature fusion of Gc, the Gc fusion peptide is
shielded by Gn subdomain A (I) and the b-ribbon domain (II) (Halldorsson et al., 2018). Binding of
VHHs that target the b-ribbon domain (blue panel) could potentially interfere with heterodimer dis-
sociation for fusion or with fusion loop insertion. The VHHs targeting domain B (yellow panel) most
likely interfere with receptor binding although specific functions have yet to be identified for this
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domain. Since the red VHH panel was unable to bind to any of the subdomains we expect these to
bind at a domain interface.
The competition observed between the SBV-specific VHHs revealed that the majority (except for
SB10) bind to one of three overlapping antigenic sites. X-ray crystallography studies previously
showed that mAb 1C11 binds to the apical end of the Gc head domain (Hellert et al., 2019). Since
SB11 and SB14 partially block antigen recognition by mAb 1C11, although not reciprocally, it
appears that the antigenic sites recognized by the majority of our VHHs partially overlap with the
antigenic site of mAb 1C11. The apical end of the Gc head domain thus appears to be highly immu-
nogenic in llamas. A fourth, independent antigenic site is defined by SB10, for which an escape
mutation at the hinge that connects the head domain to the stalk domain was identified. Intriguingly,
the same point mutation was also found in an SBV field sample from a malformed goatling in 2012
(BH 233/12–1, GenBank: KC108871, Fischer et al., 2013). The virus in this goatling possibly repli-
cated in the face of sub-neutralizing levels of antibodies that selected for this mutation. The muta-
tion could affect the binding of the antibodies directly or the mutation could alter the conformation
of Gc, leading to less efficient neutralization by SB10 or similar antibodies. We postulate that anti-
bodies similar to SB10 are produced by more than just one natural target species, and that these
antibodies pose a significant fitness cost for viral growth. As the biological role of the SBV Gc head
domain is not yet fully understood, mechanisms for antibody protection remain speculative at this
point. It becomes however apparent that binding of different antibodies to the SBV Gc head domain
may alter the tertiary or quaternary structure of the spike and influence its structural dynamics:
whereas at least two antigenic sites have been mapped to the putative trimerization interface of the
head domain, SB10 binding likely restrains the head domain’s mobility at its connection to the stalk.
Together with inhibition of host cell attachment, these mechanisms may well contribute to virus
neutralization.
Following the proof of principle experiments with the ELP-based complexes, selected VHHs were
reformatted to bispecific hIgG1Fc-VHH fusion proteins (Laventie et al., 2011). In contrast to the
ELP-based VHH complexes, the hIgG1Fc bispecific format is potentially capable of eliciting effector
function and expected to have a prolonged half-life in plasma due to FcRn binding. Orthologous
mouse and human FcgRs share ~60–70% identity, suggesting some incompatibility. However, a
recent study shows that hIgG1 binds all mouse FcgRs with affinities that are similar to binding affini-
ties of mouse IgG2a to the mouse receptors (Dekkers et al., 2017). Hence, FcgR-mediated effector
functions of the hIgG1Fc based bispecifics are expected to be maintained in mice. Production of the
two hIgG1Fc-VHH fusion proteins with the CHO cell based transient expression platform
(Daramola et al., 2014) was efficient and preliminary data suggest that the expression and purifica-
tion profiles are similar to what is usually seen with conventional bispecific antibodies. Nevertheless,
a more comprehensive characterization of the molecules is still required to fully assess the manufac-
turability of this new bispecific format.
Altogether, our study describes a novel method to rapidly screen and format VHHs into highly
potent multispecific complexes, which besides providing ammunition in the battle against (bunya)
viruses, is expected to provide novel opportunities for the development of cancer and toxin
biotherapeutics.
Materials and methods
Key resources table
Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Strain, strain
background
(virus, Ovis aries)
RVFV-35/74 (Kortekaas et al., 2011) RVFV-35/74 Recombinant virus
Strain, strain
background
(virus, Homo
sapiens)
RVFV-Clone 13 (Muller et al., 1995) RVFV-Clone 13 Natural isolate lacking
69% of the NSs gene
Continued on next page
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Continued
Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Strain, strain
background
(virus, Bos taurus)
SBV NL-F6 (Van Der Poel et al., 2014; Hulst et al., 2013) SBV NL-F6 Natural isolate
Strain, strain
background
(virus, Ovis aries)
SBV BH619 (Wernike et al., 2015b) SBV BH619 Natural isolate
Strain, strain
background (E. coli)
TG1 cells Immunosource 60502–2 Electrocompetent
cells
Strain, strain
background (E. coli)
BL21 (DE3) New England Biolabs C2527H Competent cells
Strain, strain
background
(Mus musculus)
BALB/cAnNCrl
mice
Charles River
Laboratories
BALB/cAnNCrl
Strain, strain
background
(Mus musculus)
IFNAR-/-mice
C57BL/6
FLI B6.129S2-Ifnar
1tm1Agt/Mmjax
Strain, strain
background
(yeast)
S. cerevisiae (Harmsen and De Haard, 2007a) S. cerevisiae
Cell line
Chlorocebus
aethiops
Vero E6 ATCC CRL-1586
Cell line
Spodoptera
frugiperda
Sf9-ET cells ATCC CRL-3357
Cell line
Trichoplusia ni
High Five cells Thermo Fisher
Scientific
B855-02
Recombinant
DNA reagent
pRL144 (Harmsen et al., 2005) pRL144 Phage display
vector
Peptide,
recombinant
protein
RVFV-Gnecto (de Boer et al., 2010)
Peptide,
recombinant
protein
SBV-Gchead (Wernike et al., 2017)
Recombinant
DNA reagent
Coding regions
RVFV-Gn-ecto
This paper Genscript Table 1
Recombinant
DNA reagent
Coding region
SBV-Gc-head
This paper Genscript Table 1
Recombinant
DNA reagent
pRL188 (Harmsen
et al., 2007b)
AJ811567 Yeast expression
vector
Recombinant
DNA reagent
pQE-80L Qiagen Expression plasmid
Recombinant
DNA reagent
pBAC3 Merck 70088 Baculo transfer
plasmid
Commercial
assay, kit
ELISA Streptactin
coated microplates
IBA Lifesciences 2-1501-001
Commercial
assay, kit
FlashBac
ULTRA system
Oxford Expression
Technologies
100300
Commercial
assay, kit
Lightning-Link
HRP Conjugation
Kit
Innova Biosciences AB102890
Other Gravity Flow
Strep-tactin
Sepharose column
IBA 2-1202-001
Continued on next page
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Continued
Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Other Amicon Ultra
centrifugal filters
Merck Millipore UFC900324
Other RVFV VLPs (de Boer et al., 2010) Virus-like particles
Other Ni-NTA resin Qiagen 30210
Other Protein A agarose
Fast Flow 50%
Sigma P3476
Other CHO transient
expression system
(Daramola et al., 2014) Expression system
Other Human albumin Sigma A9511
Other Mouse albumin Sigma A3139
Other Bovine albumin Sigma A7906
Other Bis-Tris NuPAGE
Novex Gels
Life Technologies 4–12% NP0322
12% NP0342
Other TMB One Component
HRP Microwell Substrate
SurModics TMBW-1000–01
Other HRP-conjugated Strep-Tactin IBA 2-1502-001 1:5000
Commercial
assay, kit
QIAamp Viral RNA kit Qiagen 52904
Commercial
assay, kit
RNA Clean and Concentrator  5 kit Zymo R1013
Commercial
assay, kit
Phusion Flash
High-Fidelity
PCR Master Mix
Thermo Fisher
Scientific
F548
Commercial
assay, kit
MagAttract
Virus mini M48 kit
Qiagen 955336
Commercial
assay, kit
DNA Clean and Concentrator-5 kit Zymo D4014
Commercial
assay, kit
Superscript III
First-Strand
Synthesis System
Invitrogen 18080051
Sequence-
based reagent
JR565 This paper PCR primers GACAATTGATG
ACACATATAGCTT
Sequence-
based reagent
JR829 This paper PCR primers ACAGAGCCTCTG
AGAAATGTCTG
Sequence-
based reagent
JR830 This paper PCR primers GATTTGCATACC
AGTATTGGTG
Antibody Polyclonal HRP-
conjugated goat
anti-llama IgG-H+L
Bethyl A160-100P IPMA (1:1000),
ELISA (1:2000)
Viruses, cells and media
Culture media and supplements were obtained from Gibco (Life Technologies, Paisley, United King-
dom) unless indicated otherwise. Virus stocks of RVFV strain Clone 13 (Muller et al., 1995) and SBV
strain NL-F6 (Van Der Poel et al., 2014) were obtained after infections at low multiplicity of infec-
tion (0.01) of Vero E6 cells (ATCC CRL-1586, Teddington, United Kingdom). Vero cells were main-
tained in Eagle’s minimal essential medium (EMEM) supplemented with 1% nonessential amino acids
(NEAA), 1% antibiotic/antimycotic (a/a) and 5% foetal bovine serum (FBS), at 37˚C with 5% CO2.
Cells were regularly tested and were mycoplasma free.
Llama immunization and phage display selection
Two adult llamas (Lama glama, #9342, #9343) were intramuscularly (hind leg) immunized with 1 ml of
RVFV strain Clone 13 (107 TCID50) and another two llamas (#9340, #9341) were inoculated via the
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same route with SBV NL-F6 (106 TCID50). Four weeks post immunization the VHH repertoire of the
individual animals was amplified by RT-PCR from peripheral blood lymphocytes and inserted into
phage display vector pRL144, as earlier described (Harmsen et al., 2005). Additionally, a library was
taken along from a llama (#3467) that was three times immunized with 20 mg RVFV VLPs (de Boer
et al., 2010) using a four week interval between immunizations 1 and 2 and a three week interval
between immunizations 2 and 3. A week post the second vaccination a blood sample was taken for
library preparation. Of note, simultaneously with the RVFV VLP antigen, this llama was also immu-
nized with influenza antigens for a different study (Harmsen et al., 2013). Libraries consisting of at
least 107 unique clones were generated and phages were rescued (Harmsen et al., 2007b). Phage
display selections were subsequently performed by consecutive rounds of biopanning using RVFV-
Gnecto and SBV-Gchead expressed with a N-terminal Twin-Strep-tag as a bait antigen coated to
Strep-Tactin coated microplates (IBA Lifesciences, Go¨ttingen, Germany). To assess the enrichment
of phages displaying RVFV-Gnecto- or SBV-Gchead-specific VHHs, parallel phage ELISA and phage dis-
play selection were performed. After panning round two or three, individual clones were picked and
grown in suspension for small-scale VHH production.
Isolation and identification of RVFV and SBV-specific VHHs
After the second or third round of panning and transduction to E. coli TG1 cells, individual colonies
were picked and the VHH expression was induced with 3 mM IPTG. Soluble VHHs, extracted from
the periplasm, were tested for binding to the RVFV-Gnecto and SBV-Gchead antigens at 10-fold
Table 1. Amino acid sequences of used domains and tags.
Protein Amino acid sequence
SBV Gchead INCKNIQSTQLTIEHLSKCMAFYQNKTSSPVVINEIISDASVDEQELIKSLNLNCNVIDRFISESSVIETQV
YYEYIKSQLCPLQVHDIFTINSASNIQWKALARSFTLGVCNTNPHKHICRCLESMQMCTSTKTDHARE
MSIYYDGHPDRFEHDMKIILNIMRYIVPGLGRVLLDQIKQTKDYQALRHIQGKLSPKSQSNLQLKGFL
EFVDFILGANVTIEKTPQTLTTLSLI
Twin Strep-tag GSAWSHPQFEKGGGSGGGSGGSAWSHPQFEK
Yeast signal peptide MMLLQAFLFLLAGFAAKISA
SpyTag AHIVMVDAYKPTK
SpyCatcher DIPTTENLYFQGAMVDTLSGLSSEQGQSGDMTIEED
SATHIKFSKRDEDGKELAGATMELRDSSGKTIS
TWISDGQVKDFYLYPGKYTFVETAAPDGYEVATAITFT
VNEQGQVTVNGKATKGDAHIDGPQGIWGQLEWKK
SnoopTag KLGDIEFIKVNK
SnoopCatcher SSGLVPRGSHMKPLRGAVFSLQKQHPDYPDIYGAI
DQNGTYQNVRTGEDGKLTFKNLSDGKYR
LFENSEPAGYKPVQNKPIVAFQIVNGEVRDVTSIVP
QDIPATYEFTNGKHYITNEPIPPKGPQGIWGQLDGHGVG
ELP (1-2-3) NL(GVPGVGVPGVGVPGEGVPGVGVPGVGVPGVGVPGVGVPGEGVP
GVGVPGVGVPGVGVPGVGVPGEGVPGVGVPGVGVPG)1-3GLL
HisTag MKGSSHHHHHH
SdyCatcher SSGLVPRGSHMASMTGGQQMGRGSSGLSGETGQSGNTTIEEDSTTHVK
FSKRDANGKELAGAMIELRNLSGQTIQSWISDGTVKVFYLMPGTYQFVE
TAAPEGYELAAPITFTIDEKGQIWVDS
SdyTag DPIVMIDNDKPIT
RVFV-Gn-A EDPHLRNRPGKGHNYIDGMTQEDATCKPVTYAGACSSFDVLLEKGK
FPLFQSYAHHRTLLEAVHDTIIAKADPPSCDLQSAHGNPCMKEKLVM
KTHCPNDYQSAHYLNNDGKMASVKCPPKYELTEDCNFCRQMT
GASLKKGSYPLQ
RVFV-Gn-ß QDLFCQSSEDDGSKLKTKMKGVCEVGVQALKKCDGQLSTAHEVVP
FAVFKNSKKVYLDKLDLKTEENGSGSGVVQIQVSGVWKKPLCVG
YERVVVKRELSA
RVFV-Gn-B NLLPDSFVCFEHKGQYKGTMDSGQTKRELKSFDISQCPKIGG
HGSKKCTGDAAFCSAYECTAQYANAYCSHANGSG
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dilution as described below (ELISA). Individual VHHs were sequenced and aligned according to the
IMGT system as described (Harmsen et al., 2000; Lefranc et al., 2003).
Production of RVFV-Gnecto and SBV-Gchead antigen
The coding regions of the RVFV-Gnecto (and smaller subdomains) and the SBV-Gchead domain
(Table 1) were gene synthesized by GenScript (Piscataway, New Jersey), and cloned into the pBAC3
baculo transfer plasmid (Merck) resulting in the following open reading frame (ORF) organization:
signal sequence GP 64 – SpyCatcher – 10 GlySer linker – domain of interest – enterokinase - Twin
Strep-tag. After rescue of the recombinant baculoviruses using the FlashBAC ULTRA system (Oxford
Expression Technologies, Oxford, United Kingdom) in Sf9-ET cells (ATCC CRL-3357) according to
the manufacturer’s instructions, protein productions were initiated in High Five cells (Thermo Fisher
Scientific, Landsmeer, The Netherlands) according to the manufacturer’s instructions. The proteins of
interest were subsequently purified from the culture supernatant using gravity flow Strep-tactin
sepharose columns (IBA) according to the manufacturer’s instructions. Finally, proteins were buffer
exchanged to TBS with 200 mM NaCl using Amicon Ultra centrifugal filters (Merck Millipore, Burling-
ton, Massachusetts).
VHH production
For medium scale production of VHHs a yeast (S. cerevisiae) expression system was used. VHH gene
fragments were either transferred from pRL144 or synthesized by GenScript and transferred into the
yeast expression vector pRL188 (Harmsen et al., 2007b). The SpyTagged, SdyTagged and Snoop-
Tagged versions of the VHHs were organized as follows: yeast signal sequence – VHH – 15 GlySer
linker – Spy/Sdy/SnoopTag – GAA linker – HisTag (Table 1). S. cerevisiae cells were induced for VHH
expression using galactose and VHHs were purified from the culture supernatant by IMAC using Ni-
NTA resin as described (Harmsen et al., 2007b). The buffer was exchanged to PBS using 3 kDa Ami-
con Ultra centrifugal filters (Merck Millipore).
ELP scaffolds
Scaffold sequences of three different lengths (Table 1), based on previous work of Howarth and col-
leagues (Zakeri et al., 2012; Veggiani et al., 2016; Li et al., 2014), were codon-optimized for
expression in E. coli and synthesized by GenScript. The gene fragments were cloned into the pQE-
80L expression plasmid (ORF organization: HisTag – SnoopCatcher – ELP(1/2/3) – SpyCatcher –
GlySer linker- ABD – Entero kinase- Twin Strep-tag) (Qiagen, Hilden, Germany). For the expression
of the scaffold that facilitated formation of a trispecific VHH complex the ORF organization was as
follows: HisTag – SnoopCatcher – ELP – SpyCatcher – ELP - SdyCatcher – GlySer linker- ABD –
Entero kinase – Twin Strep-tag. Plasmids were subsequently introduced into E. coli BL21 competent
cells by standard procedures. Transformed colonies were grown in Luria-Bertani (LB) broth and
induced by IPTG using standard procedures. Cells were subsequently lysed under denaturing condi-
tions, using 6 M guanidine hydrochloride as a denaturant. The scaffolds were purified from the
supernatants by IMAC using Ni-NTA resin. Finally, the scaffolds were refolded by buffer exchange to
PBS using 30 kDa Amicon Ultra centrifugal filters (Millipore).
Formation and purification of VHH complexes
Bivalent, bispecific and trispecific complexes were formed upon mixing of SpyTagged, Snoop-
Tagged and/or SdyTagged VHHs with ELP scaffolds with C-terminally, N-terminally and/or internal
Spy-, Snoop- or SdyCatchers. Briefly, scaffold and VHH solutions were diluted in PBS to concentra-
tions between 5–32 mM. Subsequently, solutions were mixed at a 1:3-1:4 molar ratio (scaffold:VHH)
under agitation (300 rpm) in a thermoblock (Eppendorf, Hamburg, Germany) for 3 hr at 20˚C. Of
note, for the trispecific complex the SdyTagged VHHs were incubated 3 hr at 20˚C before the Spy-
and SnoopTagged VHHs were added. When required, complexes were separated from uncoupled
VHHs by Strep-Tactin based affinity chromatography according the manufacturer’s instructions (IBA).
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Construction and small-scale production of hIgG1Fc-VHH chimeric
antibodies
Tetravalency and/or bi-specificity was achieved by cloning one VHH in frame with the human IgG1
hinge, CH2 and CH3 exons (Laventie et al., 2011). The stop codon was removed to allow transla-
tion into the other VHH domain via a flexible synthetic linker (ERKPPVEPPPPP). The secreted anti-
body is a dimer of ~110 kDa (Figure 6B). For a small scale production we stably transfected HEK
293 T cells with the resulting plasmid (pCAG hygro G1 variant) and purified bispecific antibodies
from the supernatant using protein A affinity resin as described previously for HCAbs (Drabek et al.,
2016).
Production of hIgG1Fc-VHH chimeric antibodies in CHO transient
expression system
For medium scale production, the hIgG1Fc-VHH chimeric antibodies were expressed in a CHO tran-
sient expression system as previously described (Daramola et al., 2014). The sequences for the
hIgG1Fc-VHH chimeric antibodies were synthesized by GeneArt, ThermoFisher and cloned into OriP-
containing expression vectors (Gahn and Sugden, 1995). Twenty litre cell culture volumes in dispos-
able rocking bioreactors were subsequently transiently transfected with the expression vectors. The
clarified harvest supernatant was purified using Protein A-based chromatography (Liu et al., 2010).
SDS-PAGE
Samples were denatured using SDS-PAGE sample buffer with or without DTT and heated for 7–10
min at 95˚C. Generally, samples containing 2.5–3 mg of total protein were loaded onto 4–12% or
12% Bis-Tris NuPAGENovex Gels (Life Technologies). Gels were stained with GelCode Blue Stain
Reagent (Thermo Scientific, Waltham, Massachusetts) according to the manufacturer’s instructions.
HRP conjugation of VHHs
Purified VHHs were conjugated with HRP using the Lightning-Link HRP Conjugation Kit (Innova Bio-
sciences, Cambridge, United Kingdom).
ELISAs
Strep-Tactin microplates (Cat. No. 2-1501-001, IBA) were coated with 100 ml/well of RVFV-Gnecto or
SBV-Gchead at 1 mg/mL in ELISA binding buffer (25 mM Tris-HCl, 2 mM EDTA, 140 mM NaCl, pH
7.6) overnight at 4˚C and then washed with PBS supplemented with 0.05% Tween 20 (PBST20) using
an ELISA washer (6 pulses). Plates were blocked with 300 ml/well of ELISA blocking buffer (2% w/v
skimmed milk in PBST20) for 1 hr at RT. Plates were subsequently incubated with 100 ml/well of five-
fold dilution series in blocking buffer of unconjugated (indirect ELISA) VHHs, VHH complexes or
VHH-hIgG1 fusions (starting at 10 mg/ml) for 1 hr at RT and then washed with the ELISA washer.
HRP-conjugated goat anti-llama IgG-H+L (A160-100P, Bethyl, Montgomery, Texas) diluted 1:2000 in
blocking buffer (100 ml/well) was used as a secondary antibody (1 hr at RT). For the competition
ELISA, plates were loaded with 90 ml/well of the competing VHHs at 11.11 mg/ml in blocking buffer,
followed by incubation for 1 hr at RT. Subsequently, 10 ml/well of the analyte HRP-conjugated VHHs
(concentration differs per VHH and should reach E450 0.5–0.8 in indirect ELISA) in blocking buffer
were added, followed by incubation for 1 hr at RT. In all three ELISAs, TMB One Component HRP
Microwell Substrate (TMBW-1000–01, SurModics, Minnesota) was added as a substrate. For the spe-
cies-specific albumin ELISA of the ABD containing ELP scaffold, human (A9511 Sigma), mouse
(A3139 Sigma) or bovine albumin (A7906 Sigma) was coated at a 10 mg/ml concentration. Plates
were blocked with 300 ml/well of casein blocking buffer (2% casein in PBST20) for 1 hr at RT. Plates
were subsequently incubated with 100 ml/well ABD containing ELP scaffold in a dilution series.
Strep-Tactin-HRP conjugate (2-1502-001, IBA) diluted 1:5000 in casein blocking buffer (100 ml/well)
was used as a secondary antibody (1 hr at RT).
Immunoperoxidase monolayer assay (IPMA)
Cells were fixed with 4% v/v paraformaldehyde for 15 min at RT and then washed with PBST20. For
cell permeabilization, the fixed cells were incubated with PBS supplemented with 1% v/v Triton
X-100 for 5 min at RT. After three washes with PBST20, plates were subsequently blocked with IPMA
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blocking buffer (5% v/v horse serum in PBS) and incubated for 1 hr at 37˚C. Diluted primary antibod-
ies (VHHs) in blocking buffer (100 mL/well) were added. Plates were incubated for 1 hr at 37˚C and
then washed three times with PBST20. Subsequently, a HRP-conjugated goat anti-llama IgG H+L sec-
ondary antibody (Bethyl, A160-100P) in blocking buffer (1:1000, 100 mL/well) was added. Plates were
incubated for 1 hr at 37˚C and then washed three times with PBST20. For staining, 100 mL/well of a
0.2 mg/mL amino ethyl carbazole (AEC) solution in 500 mM acetate buffer (pH 5.0), 88 mM H2O2
was added as a substrate. Plates were incubated for 15–30 min at RT. Titers were calculated as the
50% tissue culture infective dose (TCID50)/mL using the Spearman-Ka¨rber method.
SB10 escape mutant selection
An escape mutant was selected after serial passaging of SBV NL-F6 under selective pressure by
SB10. Initially, 1 ml of 104 TCID50/ml virus suspension was incubated with 1 ml of SB10 solution at 10
mg/ml for 2 hr at RT. The virus-VHH mixture was then inoculated into T25 flasks seeded with 8  105
Vero E6 cells, and subsequently incubated for 48–96 hr at 37˚C with 5% CO2. Virus harvested from
the culture supernatants and again subjected to SB10-mediated neutralization was used for sequen-
tial rounds of passaging. Suspected mutants from the sixth passage exhibiting cytopathic effects
were selected for total RNA isolation using the QIAamp Viral RNA kit (Qiagen). Isolated RNA was
purified and concentrated using the RNA Clean and Concentrator-5 kit (Zymo, Irvine, California)
according to the instructions of the manufacturer. The SuperScript III First-Strand Synthesis System
(Invitrogen) in combination with primer JR565 (GACAATTGATGACACATATAGCTT) was used to
reverse transcribe the SBV Gc head domain RNA. An SBV Gchead-specific PCR product was amplified
using the Phusion Flash High-Fidelity PCR Master Mix (Thermo Scientific) in combination with primer
JR829 (ACAGAGCCTCTGAGAAATGTCTG) and JR830 (GATTTGCATACCAGTATTGGTG). PCR
products were purified and concentrated using the DNA Clean and Concentrator-5 kit (Zymo).
Finally, samples were sent to BaseClear (Leiden, The Netherlands) for Sanger sequencing. SBV NL-
F6 without being passaged and SBV NL-F6 passaged without prior incubation with SB10 were used
as controls.
Virus neutralization tests
RVFV neutralization was assessed with the use of a highly sensitive VNT test as described
(Wichgers Schreur et al., 2017). SBV neutralization was assessed with the following method. In stan-
dard 96-well cell culture plates, 50 ml of two-fold dilutions of VHHs (starting at approximately 1000
nM) were incubated with 50 ml of a 104.2 TCID50/ml SBV suspension for 2 hr at RT, before adding
them to 1.5  104 Vero E6 cells/well. VHH-SBV complexes and cells were incubated for 48 hr at 37˚C
with 5% CO2, and subsequently stained using IPMA. The neutralization capacity was calculated as
ND50.
RVFV challenge experiments
Six-week-old female BALB/cAnNCrl mice (Charles River Laboratories) were randomly divided into
groups of 5 mice, kept in type III filter-top cages under BSL-3 conditions, and allowed to acclimatize
for 6 days. The group size was computed (power 80%) with an estimated mortality (including eutha-
nasia at HEP) in the non-treated control group of 95% and an estimated mortality in the treated
group of 15–25% http://clincalc.com/stats/samplesize.aspx. Mice were prophylactically (t =  6 hr) or
therapeutically (t = 18 hr) treated with purified VHH complexes (150 mg) or antibodies (150–200 mg)
via the intraperitoneal route (in 100 ml PBS). Mice were challenged at t = 0 via intraperitoneal route
with 103 TCID50 of recombinant RVFV strain 35/74 (Kortekaas et al., 2011) in 100 ml medium. Chal-
lenged mice were closely monitored and humanely euthanized after reaching a humane endpoint.
SBV challenge experiments
Eighteen male and female IFNAR-/-mice with a C57BL/6 genetic background (B6.129S2-Ifnar1t-
m1Agt/Mmjax) were obtained from the specific pathogen free breeding unit of the Friedrich-Loef-
fler-Institut. The animals were 4 to 6 weeks old and were randomly divided into 3 groups of 6
animals with equally distributed sexes. The group size calculation followed the same assumptions as
for the RVFV challenge experiment. 24 hr prior to challenge infection, the mice were intraperitone-
ally treated with 200 mg (SB10-ELP2ABD-SB10) or 100 mg (SB10-ELP2ABD-SB9) of purified VHH
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complexes diluted in 100 ml PBS/mouse. Control animals received an equal volume of PBS. The mice
were subcutaneously infected with SBV strain BH619 (Wernike et al., 2015b) (105 TCID50/mouse,
diluted in 100 ml PBS). After challenge infection, the animals were closely monitored and weighed
daily for 9 consecutive days. On days 3 and 7 post infection, EDTA blood samples were collected for
RT-qPCR analyses. Animals showing severe clinical symptoms were immediately humanely eutha-
nized. The remaining animals were euthanized after 21 days. At necropsy, serum and EDTA blood
samples as well as tissue samples from liver and spleen were collected. RNA extraction was per-
formed using a KingFisher 96 Flex (Thermo Scientific) and the MagAttract Virus Mini M48 Kit (Qia-
gen) according to the instructions of the manufacturer. For RT-qPCR analyses a previously described
SBV-S-segment-specific assay was used in combination with the beta actin housekeeping gene as
internal control (Bilk et al., 2012; Tauscher et al., 2017). For quantification of viral RNA, an external
SBV standard was included.
Statistical analyses
When appropriate, data was statistically analysed with GraphPad Prism version 8 software. Specific
tests used are described in the figure legends.
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